临床前CDMO研发筛选相关化合物

CDMO是Contract Development and Manufacturing Organization的缩写，即合同定制研发生产组织。它是一种为制药企业及生物技术公司提供医药（特别是创新药）工艺研发及制备、工艺优化、放大生产、注册和验证批生产以及商业化生产等定制服务的机构. 在传统代工基础上增加了研发和工艺优化能力，是高技术壁垒的工艺研发能力与规模生产能力的深度结合. 1, 工艺开发与优化：创新性合成路线设计、工艺参数优化. 2, 中试放大：实验室工艺向规模化生产的转化 3, 注册批生产：支持客户新药申报的验证批生产. 4, 商业化生产：药品上市后的大规模生产供应. 全球医药CDMO行业保持较高景气度。根据弗若斯特沙利文预测：2026年全球CDMO市场规模：预计达1,189亿美元 2033年全球CDMO市场规模：预计达3,385亿美元. CDMO作为医药产业链专业化分工的产物，已经从单纯的CMO代工模式升级为"研发+生产"一体化的高附加值服务。当前，在多肽、ADC、CGT等新型药物赛道的驱动下，全球及中国CDMO市场保持高速增长。中国CDMO企业凭借完整的供应链体系、工程师红利和一体化服务能力，全球市占率有望持续提升，行业正从"成本优势"竞争迈向"体系优势"竞争的新阶段。
如有产品调研服务, 请致函联系我们

客户展示

临床前CDMO研发化合物筛选

CAS: 254964-60-8

Tasquinimod

中文名称:他喹莫德
CAS号:254964-60-8
分子式: C20H17F3N2O4 分子量: 406.36
产品形式: free base
研发状态: Withdrawn
研发用途: Prostate Cancer; Bone-only Metastatic Castration-Resistant Prostate Cancer (CRPC)
研究机构: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
研发日期: Mar-15
研发阶段: Phase 1
Tasquinimod (ABR-215050) is an orally active antiangiogenic agent by allosterically inhibiting HDAC4 signalling. Phase 3.

CAS: 2549174-42-5

Lirafugratinib

CAS号:2549174-42-5
分子式: C28H24FN7O2 分子量: 509.54
产品形式: free base
研发状态: Active not recruiting
研发用途: FGFR2 Amplification; FGFR2 Gene Mutation; FGFR2 Gene Fusion/Rearrangement; FGFR2 Gene Translocation; FGFR2 Gene Activation; Intrahepatic Cholangiocarcinoma; Cholangiocarcinoma; Other Solid Tumors Adult
研究机构: Relay Therapeutics Inc.
研发日期: September 2 2020
研发阶段: Phase 1 : Phase 2
Lirafugratinib (RLY-4008) is an orally active and selective inhibitor of FGFR2.

CAS: 254750-02-2

Emricasan (IDN-6556)

中文名称:(S)-3-((s)-2-(2-(2-叔丁基苯基氨基)-2-氧代乙酰氨基)丙酰胺)-4-氧代-5-(2,3,5,6-四氟苯氧基)戊酸
CAS号:254750-02-2
分子式: C26H27F4N3O7 分子量: 569.50
产品形式: free base
研发状态: Unknown status
研发用途: Decompensated Cirrhosis
研究机构: Conatus Pharmaceuticals Inc.
研发日期: June 28 2017
研发阶段: Phase 2
Emricasan (IDN-6556, PF 03491390, PF-03491390) is a potent irreversible pan-caspase inhibitor. Emricasan is an inhibitor of Zika virus infection.

CAS: 25332-39-2

Trazodone HCl

中文名称:盐酸曲唑酮
CAS号:25332-39-2
分子式: C19H22ClN5O.HCl 分子量: 408.32
产品形式: Hydrochloride
研发状态: Recruiting
研发用途: Obstructive Sleep Apnea
研究机构: Brigham and Women''s Hospital
研发日期: January 1 2024
研发阶段: Phase 1 : Phase 2
Trazodone HCl (AF-1161, KB-831) is an antidepressant belonging to the class of serotonin receptor antagonists and reuptake inhibitors for treatment of anxiety disorders.

CAS: 25316-40-9

Doxorubicin (Adriamycin) HCl

中文名称:盐酸阿霉素
CAS号:25316-40-9
分子式: C27H29NO11.HCl 分子量: 579.98
产品形式: Hydrochloride
研发状态: Active not recruiting
研发用途: Breast Cancer Female
研究机构: Mansoura University
研发日期: December 25 2023
研发阶段: Phase 2
Doxorubicin (Adriamycin, NSC 123127, DOX, Hydroxydaunorubicin) HCl is an antibiotic agent that inhibits DNA topoisomerase II and induces DNA damage, mitophagy and apoptosis in tumor cells. Doxorubicin reduces basal phosphorylation of AMPK. Doxorubicin is used in the concomitant treatment of HIV-infected patients but is found to be at high risk of HBV reactivation.

CAS: 251945-92-3

Derenofylline (SLV320)

中文名称:4-((2-苯基-7H-吡咯并[2,3-d]嘧啶-4-基)氨基)环己醇
CAS号:251945-92-3
分子式: C18H20N4O 分子量: 308.38
产品形式: Free Base
研发状态: Terminated
研发用途: Acute Decompensated Heart Failure; Renal Dysfunction
研究机构: Solvay Pharmaceuticals
研发日期: Feb-09
研发阶段: Phase 2
Derenofylline (SLV320) is a selective and potent adenosine A1 antagonist with Ki of 1 nM. Derenofylline shows selective for adenosine A1 over A2A, A2B, and A3 receptors with Ki of 398 nM, 3981 nM, and 200 nM, respectively.